Journal of the Neurological Sciences
Volume 288, Issue 1 , Pages 1-12 , 15 January 2010

The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS)

  • Michael J. Strong

      Affiliations

    • Corresponding Author InformationRoom C7-120, University Hospital, LHSC, 339 Windermere Road, London, Ontario, Canada N6A 5A5. Tel.: +1 519 663 3874; fax: +1 519 663 3609.

Received 7 July 2009 ,Revised 27 August 2009 ,Accepted 25 September 2009.

References 

  1. Strong MJ. The evidence for ALS as a multisystems disorder of limited phenotypic expression. Can J Neurol Sci. 2001;28:283–298
  2. Strong MJ. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:323–338
  3. Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:131–146
  4. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillée S, Rule M, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113–117
  5. Moisse K, Strong MJ. Innate immunity in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762:1083–1093
  6. Sargsyan SA, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia. 2005;51:241–253
  7. Nguyen MD, D'Aigle T, Gowing G, Julien J-P, Rivest S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2004;24:1340–1349
  8. Ferri A, Nencini M, Casciati A, Cozzolino M, Angelini DF, Longone P, et al. Cell death in amyotrophic lateral sclerosis: interplay between neuronal and glial cells. FASEB J. 2004;18:1261–1293
  9. Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?. J Neuropathol Exp Neurol. 2005;64:649–664
  10. Mather K, Watts FZ, Carroll M, Whitehead P, Swash M, Cairn N, et al. Antibody to an abnormal protein in amyotrophic lateral sclerosis identifies Lewy body-like inclusion in ALS and Lewy bodies in Parkinson's disease. Neurosci Lett. 1993;160:13–16
  11. Migheli A, Pezzulo T, Attanasio A, Schiffer D. Peripherin immunoreactive structures in amyotrophic lateral sclerosis. Lab Invest. 1993;68:185–191
  12. Malaspina A, Kaushik N, de Belleroche J. A 14-3-3 mRNA is up-regulated in amyotrophic lateral sclerosis spinal cord. J Neurochem. 2000;75:2511–2520
  13. Kawamoto Y, Akiguchi I, Nakamura A, Budka H. 14-3-3 proteins in Lewy body-like hyaline inclusion in patients with sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2004;108:531–537
  14. Chou SM, Wang HS, Komai K. Colocalization of NOS and SOD1 in neurofilament accumulation within motor neurons of amyotrophic lateral sclerosis: an immunohistochemical study. J Chem Neuroanat. 1996;10:249–258
  15. Ince PG, Tomkins J, Slade JY, Thatcher NM, Shaw PJ. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropathol Exp Neurol. 1998;57:895–904
  16. Shibata N, Hirano A, Klapporth K. Immunohistochemical demonstration of Cu/Zn superoxide dismutase in the spinal cord of patients with familial amyotrophic lateral sclerosis. Acta Histochem Cytochem. 1993;26:619–621
  17. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602–611
  18. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133
  19. Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–1208
  20. Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208–1211
  21. Bergeron C, Beric-Maskarel K, Muntasser S, Weyer L, Somerville M, Percy ME. Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons. J Neuropathol Exp Neurol. 1994;53:221–230
  22. Wong N, He BP, Strong MJ. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J Neuropathol Exp Neurol. 2000;59:972–982
  23. Menzies FM, Grierson AJ, Cookson MR, Heath PR, Tomkins J, Figlewicz DA, et al. Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis. J Neurochem. 2002;82:1118–1128
  24. Bolognani F, Perrone-Bizzozero NI. RNA–protein interactions and control of mRNA stability in neurons. J Neurosci Res. 2008;86:481–489
  25. Lin AC, Holt CE. Function and regulation of local axonal translation. Curr Opin Neurobiol. 2008;18:60–68
  26. Keene J, Tenenbaum SA. Eukaryotic mRNPs may represent posttranscriptional operons. Mol Cell. 2002;9:1161–1167
  27. Keene JD. RNA regulons: coordination of post-transcriptional events. Nat Rev Genet. 2007;8:533–543
  28. Anderson P, Kedersha N. RNA granules. J Cell Biol. 2006;172:803–808
  29. Lukong KE, Chang K, Khandjian EW, Richard S. RNA-binding proteins in human genetic disease. Trends Genet. 2008;24:416–425
  30. Wang I-F, Wu L-S, Chang H-Y, Shen C-KJ. TDP-43, the signature protein of FTLD-U, is a neuronal activity responsive factor. J Neurochem. 2008;105:797–806
  31. Hirokawa N. mRNA transport in dendrites: RNA granules, motors and tracks. J Neurosci. 2006;26:7139–7142
  32. Kanai Y, Dohmae N, Hirokawa N. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron. 2004;43:513–525
  33. Kedersha N, Stoecklin G, Ayodele M, Yacono P, Lykke-Andersen J, Fritzler MJ, et al. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol. 2005;169:871–884
  34. Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. Trends Biochem Sci. 2008;33:141–150
  35. Barbee SA, Estes PS, Cziko A-M, Hillebrand J, Luedeman RA, Coller JM, et al. Staufen- and FMRP-containing neuronal RNPs are structurally and functionally related to somatic P bodies. Neuron. 2006;52:997–1009
  36. Lowery AJ, Miller N, McNeill RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res. 2008;14:360–365
  37. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668–1672
  38. Gao F-B. Posttranscriptional control of neuronal development by microRNA networks. Trends Neurosci. 2008;31:20–26
  39. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, et al. A brain-specific microRNA regulates dendritic spine development. Nature. 2006;439:283–289
  40. Nelson PT, Keller JN. RNA in brain disease: no longer just “the messenger in the middle”. J Neuropathol Exp Neurol. 2007;66:461–468
  41. Nelson PT, Wang W-X, Rajeev BW. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008;18:130–138
  42. Hébert SS, De Strooper B. Alteration of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009;32:199–206
  43. Boissonneault V, Plante I, Rivest S, Provost P. MicroRNA-298 and microRNA-328 regulate expression of mouse β-amyloid precursor protein converting enzyme 1. J Biol Chem. 2009;284:1971–1981
  44. Saba R, Goodman CD, Huzarewich RLCH, Robertson C, Booth SA. miRNA signature of prion induced neurodegeneration. PLoS ONE. 2008;3:e3652
  45. Sun BK, Tsao H. Small RNAs in development and disease. J Am Acad Dermatol. 2008;59:725–737
  46. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA?. RNA. 2005;11:1753–1761
  47. Gregory RI, Yan K, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, et al. The microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432:235–240
  48. Liu X, Fortin K, Mourleatos Z. MicroRNAs: biogenesis and molecular functions. Brain Pathol. 2008;18:121
  49. Rossi JJ. RNAi and the P-body connection. Nat Cell Biol. 2005;7:643–644
  50. Jabri E. P-bodies take a RISC. Nat Struct Mol Biol. 2005;12:564
  51. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol. 2005;7:719–726
  52. Li Q, Lee J-A, Black DL. Neuronal regulation of alternative pre-mRNA splicing. Nat Rev Neurosci. 2007;8:819–831
  53. Corbo M, Hays AP. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J Neuropathol Exp Neurol. 1999;51:531–537
  54. Robertson J, Doroudchi MM, Nguyen MD, Durham HD, Strong MJ, Shaw G, et al. A neurotoxic peripherin splice variant in a mouse model of ALS. J Cell Biol. 2003;160:939–949
  55. Xiao S, Tjostheim S, Sanelli T, McLean JR, Horne P, Fan Y, et al. An aggregate-inducing peripherin isoform generated through intron retention is upregulated in amyotrophic lateral sclerosis and associated with disease pathology. J Neurosci. 2008;28:1833–1840
  56. Sanelli T, Xiao S, Horne P, Bilbao J, Zinman L, Robertson J. Evidence that TDP-43 is not the major ubiquitinated target within the pathological inclusions of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2007;66:1147–1153
  57. Lin C-LG, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589–602
  58. Meyer T, Fromm A, Münch C, Schwalenstöcker B, Fray AE, Ince PG, et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci. 1999;170:45–50
  59. Honig LS, Chambliss DD, Bigio EH, Carroll SL, Elliott JL. Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls. Neurology. 2000;55:1082–1088
  60. Flowers JM, Powell JF, Leigh PN, Andersen P, Shaw CE. Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Ann Neurol. 2001;49:643–649
  61. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371:2120–2133
  62. Zhang HL, Pan F, Hong D, Shenoy SM, Singer RH, Bassell GJ. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J Neurosci. 2003;23:6627–6637
  63. Zhang H, Xing L, Rossoll W, Wichterle H, Singer RH, Bassell GJ. Multiprotein complexes of the survival of motor neuron protein SMN with gemins traffic to neuronal processes and growth cones of motor neurons. J Neurosci. 2006;26:8622–8632
  64. Rossoll W, Kröning A-K, Ohndorf U-M, Steegborn C, Jablonka S, Sendtner M. Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons?. Hum Mol Genet. 2002;11:93–105
  65. McWhorter ML, Monani UR, Burghes AHM, Beattie CE. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol. 2009;162:919–931
  66. Wu D, Wenhao Y, Kishikawa H, Folkerth RD, Iafrate AJ, Shen Y, et al. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol. 2007;62:609–617
  67. Hatzi E, Badet J. Expression of receptors for human angiogenin in vascular smooth muscle cells. Eur J Biochem. 1999;260:825–832
  68. Yamasaki S, Ivanov P, Hu G, Anderson P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J Cell Biol. 2009;185:35–42
  69. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, et al. ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nat Genet. 2006;34:411–413
  70. Gellera C, Colobrita C, Ticozzi N, Castellotti B, Bragato C, Ratti A, et al. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics. 2008;9:33–40
  71. Crabtree B, Thiyagarajan N, Prior SH, Wilson P, Iyer S, Ferns T, et al. Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochem. 2007;46:11810–11818
  72. Corrado L, Battistini S, Penco S, Bergamaschi L, Testa L, Ricci C, et al. Variations in the coding and regulatory sequences of the angiogenin (ANG) gene are not associated to ALS (amyotrophic lateral sclerosis) in the Italian population. J Neurol Sci. 2007;258:123–127
  73. van Es MA, Diekstra FP, Baas F, Bourque PR, Schelhaas HJ, Strengman E, et al. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology. 2009;72:287–288
  74. Gao X, Xu Z. Mechanisms of action of angiogenin. Acta Biochim Biophys Sin. 2008;40:619–624
  75. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001;28:131–138
  76. Zheng C, Nennesmo I, Fadeel B, Henter J-I. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2004;56:564–567
  77. Wang Y, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA, et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci. 2007;27:304–307
  78. Kieran D, Sebastia J, Greenway MJ, King MA, Connaughton D, Concannon CG, et al. Control of motor neuron survival by angiogenin. J Neurosci. 2008;28:14056–14061
  79. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34:383–394
  80. Chen Y-Z, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74:1128–1135
  81. Chen Y-Z, Hashemi SH, Anderson SK, Huang Y, Moreira M-C, Lynch DR, et al. Senataxin, the yeast Sen1p othologue: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neruon disease. Neurobiol Dis. 2006;23:97–108
  82. Zhao Z-H, Chen W-Z, Wu Z-Y, Wang N, Zhao G-X, Chen W-J, et al. A novel mutation in senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:118–122
  83. Grohmann K, Shuelke M, Diers A, Hoffmann K, Lucke B, Adams C, et al. Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet. 2001;29:75–77
  84. Tanner NK, Linder P. DExD/H Box RNA helicases: from generic motors to specific dissociation functions. Mol Cell. 2001;8:251–262
  85. Hargrove JL, Schmidt FH. The role of mRNA and protein stability in gene expression. FASEB J. 1989;3:2360–2370
  86. Arao Y, Kikuchi A, Kishida M, Yonekura M, Inoue A, Yasuda S, et al. Stability of A+U-rish element binding factor 1 (AUF-1)-binding messenger ribonucleic acid correlates with the subcellular relocalization of AUF1 in the rat uterus upon estrogen treatment. Mol Endocrinol. 2004;18:2255–2267
  87. Wilson GM, Lu J, Sutphen K, Suarez Y, Sinha S, Brewer B, et al. Phosphorylation of p40AUF1 regulates binding to A–U-rich mRNA-destabilizing elements and protein-induced changes in ribonucloprotein structure. J Biol Chem. 2003;278:33039–33048
  88. Gringhuis SI, García-Vallejo JJ, van het Hof B, van Dijk W. Convergent actions of IκB kinase β and protein kinase Cδ modulate mRNA stability through phosphorylation of 14-3-3β complexed with tristetraprolin. Mol Cell Biol. 2005;25:6454–6463
  89. Sun L, Stoecklin G, van Way S, Hinkovska-Galcheva V, Guo R-F, Anderson P, et al. Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-α mRNA. J Biol Chem. 2007;282:3766–3777
  90. Szaro BG, Strong MJ. Post-transcriptional control of neurofilaments: new roles in development, regeneration and neurodegenerative disease. Trends Neurosci in press.
  91. Ge W, Leystra-Lantz C, Wen W, Strong MJ. Selective loss of trans-acting instability determinants of neurofilament mRNA in amyotrophic lateral sclerosis spinal cord. J Biol Chem. 2003;278:26558–26563
  92. Strong MJ, Volkening K, Hammond R, Yang W, Strong WL, Leystra-Lantz C, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007;35:320–327
  93. Ge WW, Volkening K, Leystra-Lantz C, Jaffe H, Strong MJ. 14-3-3 protein binds to the low molecular weight neurofilament (NFL) mRNA 3′ UTR. Mol Cell Neurosci. 2007;34:80–87
  94. Ge WW, Wen W, Strong WL, Leystra-Lantz C, Strong MJ. Mutant copper/zinc superoxide dismutase binds to and destabilizes human low molecular weight neurofilament mRNA. J Biol Chem. 2005;280:118–124
  95. Cañete-Soler R, Wu J, Zhai J, Shamim M, Schlaepfer WW. p190RhoGEF binds to a destabilizing element in the 3′ untranslated region of light neurofilament subunit mRNA and alters the stability of the transcript. J Biol Chem. 2001;276:32046
  96. Cañete-Soler R, Silberg DG, Gershon MD, Schlaepfer WW. Mutation in neurofilament transgene implicates RNA processing in the pathogenesis of neurodegenerative disease. J Neurosci. 1999;19:1272–1283
  97. Nie Z, Wu J, Zhai J, Lin H, Ge W, Schlaepfer WW, et al. Untranslated element in neurofilament mRNA has neuropathic effect on motor neurons of transgenic mice. J Neurosci. 2002;22:7662–7670
  98. Lin H, Zhai J, Cañete-Soler R, Schlaepfer WW. 3′ Untranslated region in a light neurofilament (NF-L) mRNA triggers aggregation of NF-L and mutant superoxide dismutase 1 proteins in neuronal cells. J Neurosci. 2004;24:2716–2726
  99. Lin H, Zhai J, Schlaepfer WW. RNA-binding protein is involved in aggregation of light neurofilament protein and is implicated in the pathogenesis of motor neuron degeneration. Hum Mol Genet. 2005;14:3643–3659
  100. Zhang H, Tan C-F, Mori F, Tanji K, Kakita A, Takahashi H, et al. TDP-43-immunoreactive neuronal and glial inclusions in the neostriatum in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008;115:115–122
  101. Higashi S, Eizo I, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Appearance of TDP-43 in Japanese frontotemporal lobar degeneration with ubiquitin-positive inclusions. Neurosci Lett. 2007;419:213–218
  102. Mackenzie IRA, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427–434
  103. Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM, et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol. 2008;115:133–145
  104. Mishra M, Paunesku T, Woloschak GE, Siddique T, Zhu L, Lin S, et al. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol. 2007;114:81–94
  105. Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol. 2007;114:31–38
  106. Davidson Y, Kelley T, Mackenzie IRA, Pickering-Brown S, Du Plessis D, Neary D, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol. 2007;113:521–533
  107. Probst A, Taylor KI, Tolnay M. Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol. 2007;114:335–345
  108. Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007;66:152–157
  109. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171:227–240
  110. Nakashima-Yasuda H, Kunihiro U, Robinson J, Xie SX, Hurtig H, Duda JE, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114:221–229
  111. Lee EB, Lee VMY, Trojanowski Q, Neumann M. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol. 2008;115:305–311
  112. Yokoseki A, Shiga A, Tan C-F, Tagawa A, Kaneko H, Koyama A, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol. 2008;63:538–542
  113. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol. 2008;63:535–538
  114. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572–574
  115. Winton MJ, Van Deerlin VM, Kwong LK, Yuan W, Wood EM, Yu CE, et al. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett. 2008;582:2252–2256
  116. Kühnlein P, Sperfeld A-D, Vanmassenhove B, Van Deerlin V, Lee VMY, Trojanowski JQ, et al. Two German kindreds with familial amytrophic lateral sclerosis due to TARDBP mutations. Arch Neurol. 2008;65:1185–1189
  117. Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P, et al. Tardpb mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol. 2008;65:470–473
  118. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histological analysis. Lancet Neurol. 2008;7:416
  119. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genetics. 2008;4:e1000193
  120. Corrado L, Ratti A, Gellera C, Buratti E, Castellotti B, Carlomagno Y, et al. High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Hum Mutat. 2009;30:688–694
  121. Del Bo R, Ghezzi S, Corti S, Pandolfo M, Ranieri M, Santoro D, et al. TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol. 2009;16:727–732
  122. Ou S-HI, Wu F, Harrich D, García-Martínez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69:3584–3596
  123. Buratti E, Dörk T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO. 2001;20:1774–1784
  124. Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276:36337–36343
  125. Wang H-Y, Wang I-F, Bose J, Shen CKJ. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics. 2004;83:130–139
  126. Wang I-F, Reddy NM, Shen CKF. Higher order arrangement of the eukaryotic nuclear bodies. Proc Natl Acad Sci USA. 2002;99:13583–13588
  127. Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 2008;13:867–878
  128. Abhyankar MM, Urekar C, Reddi PP. A novel CpG-free vertebrate insulator silences the testis-specific SP-10 gene in somatic tissues. J Biol Chem. 2007;282:36143–36154
  129. Ayala YM, Pagani F, Baralle FE. TDP-43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett. 2006;580:1339–1344
  130. Buratti E, Brindisi A, Pagani F, Baralle FE. Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance. Am J Hum Genet. 2004;74:1322–1325
  131. Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ. Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy. Brain Res. 2009;1249:202–211
  132. Parker R, Sheth U. P bodies and the control of mRNA translation and degradation. Mol Cell. 2007;25:635–646
  133. Makeyev AV, Liebhaber SA. The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. RNA. 2002;8:265–278
  134. Wilhelm JE, Vale RD. RNA on the move: the mRNA localization pathway. J Cell Biol. 1993;123:269–274
  135. Krichevsky AM, Kosik KS. Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron. 2001;32:683–696
  136. Chabanon H, Mickleburgh I, Hesketh J. Zipcodes and postage stamps: mRNA localisation signals and their trans-acting binding proteins. Brief Funct Genomic Proteomic. 2004;3:240–256
  137. Shyu AB, Wilkinson MF. The double lives of shuttling mRNA binding proteins. Cell. 2000;102:135–138
  138. Volkening K, Leystra-Lantz C, Strong MJ. Human low molecular weight neurofilament (NFL) mRNA interacts with a predicted p190RhoGEF homologue (RGNEF). Amyotroph Lateral Scler. Jun 1 2009;1–7[Electronic publication ahead of print]
  139. Iko Y, Kodama TS, Kasai N, Oyama T, Morita EH, Muto T, et al. Domain architectures and characterization of an RNA-binding protein, TLS. J Biol Chem. 2004;279:44834–44840
  140. Bisbal M, Wojnacki J, Peretti D, Ropolo A, Sesma J, Jausoro I, et al. KIF4 mediates anterograde translocation and positioning of ribosomal constituents to axons. J Biol Chem. 2009;284:9489–9497
  141. Levy JR, Holzbaur ELF. Cytoplasmic dynein/dynactin function and dysfunction in motor neurons. Int J Devl Neuroscience. 2006;24:103–111
  142. Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, Bowen S, et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science. 2003;300:808–812
  143. Münch C, Rosenbohm A, Sperfeld A-D, Uttner I, Reske S, Krause BJ, et al. Hetereozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol. 2005;58:777–780
  144. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, et al. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33:455–456
  145. Landers JE, Melki J, Meininger V, Glass JD, Van den Berg LH, van Es MA, et al. Reduced expression of kinesin-associated protein3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2009;106:9004–9009
  146. Shan X, Tashiro H, Lin C-LG. The identification and characterization of oxidized RNAs in Alzheimer's disease. J Neurosci. 2003;23:4913–4921
  147. Tanaka M, Chock PB, Stadtman ER. Oxidized messenger RNA induces translation errors. Proc Natl Acad Sci USA. 2007;104:66–71
  148. Nunomura A, Moreira PI, Takeda A, Smith A, Perry G. Oxidative damage and neurodegeneration. Curr Med Chem. 2007;14:2968–2975
  149. Chang Y, Kong Q, Shan X, Tian G, Ilieva H, Cleveland DW, et al. Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS ONE. 2008;3:e2849
  150. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62
  151. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet. 2001;29:166–173
  152. Yang Y, Hentati A, Deng H-X, Dabbagh O, Sasaki T, Hirano M, et al. The gene encoding alsin, a protein with three guanine–nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001;29:160–165
  153. Hentati A, Bejaoui K, Pericak-Vance MA, Hentati F, Speer MC, Hung W-Y, et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33–q35. Nat Genet. 1994;7:425–428
  154. Ben Hamida M, Hentati F, Ben Hamida C. Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis). Brain. 1990;113:347–363
  155. Hand CK, Khoris J, Salachas F, Gros-Louis F, Simoes Lopes AA, Mayeux-Portas V, et al.  A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. Am J Hum Genet. 2002;70:251–256
  156. Hentati A, Ouahchi K, Pericak-Vance MA, Nijhawan D, Ahmad A, Yang Y, et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15–q22 markers. Neurogenetics. 1998;2:55–60
  157. Abalkhail H, Mitchell J, Habgood J, Orrell R, de Belleroche J. A new familial amyotrophic lateral sclerosis locus on chromosome 16q12.1–16q12.2. Am J Hum Genet. 2003;73:383–389
  158. Ruddy DM, Parton MJ, Al-Chalabi A, Lewis CM, Vance D, Smith BN, et al. Two families with familal amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am J Hum Genet. 2003;73:396
  159. Sapp PC, Hosler BA, McKenna-Yasek D, Chin W, Gann A, Genise H, et al. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet. 2003;73:397–403
  160. Nishimura AL, Mitne-Neto M, Silva HCA, Richieri-Costa A, Middleton S, Cascio D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:822–831
  161. Nishimura AL, Mitne-Neto M, Silva HCA, Oliveira JRM, Vainzof M, Zatz M. A novel locus for late onset amyotrophic lateral sclerosis/motor neurone disease variant at 20q13. J Med Genet. 2004;41:315–320
  162. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5″-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705
  163. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, et al. Clinical characteristics of a family with chromosome 17-linked disinhibition–dementia–parkinsonism–amyotrophy complex. Neurology. 1994;44:1878–1884
  164. Wilhelmsen KC, Forman MS, Rosen HJ, Alving LI, Goldman J, Feiger J, et al. 17q-linked frontotemporal dementia–amyotrophic lateral sclerosis without tau mutations with tau and α-synuclein inclusions. Arch Neurol. 2004;61:398–406
  165. Zarranz JJ, Ferrer I, Lezcano E, Forcadas MI, Eizaguirre B, Atarés B, et al. A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease. Neurology. 2005;64:1578–1585
  166. Li X, Lu L, Bush DJ, Zhang X, Zheng L, Suswam EA, et al. Mutant copper–zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to the adenine/uridine-rich stability elements in the vascular endothelial growth factor 3′-untranslated region. J Neurochem. 2009;108:1032–1044
  167. Lu L, Zheng I, Viera L, Suswam E, Li Y, Li X, et al. Mutant Cu/Zn superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J Neurosci. 2007;27:7929–7938
  168. Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet. 2008;17:3631–3642

PII: S0022-510X(09)00889-2

doi: 10.1016/j.jns.2009.09.029

Journal of the Neurological Sciences
Volume 288, Issue 1 , Pages 1-12 , 15 January 2010

Article Tools

* Image Usage & Resolution